Abstract
Background: The Kawaguchi-Gayet (K-G) classification is a validated system to stratify open liver resections by complexity and postoperative complications. We hypothesized that K-G classification could be used to create and implement risk-stratified post-hepatectomy pathways (RSPHPs) to reduce length of stay (LOS) and variation in care. Methods: Clinicopathologic data from hepatectomy patients (1/2017-6/2020) were abstracted from a prospective database. All open hepatectomies were assigned to groups based on 2 levels of K-G classification, and corresponding RSPHPs were created to decrease LOS by 1 day compared to patients who were historically treated without a pathway: Low-Intermediate (open K-G I/II) and High-Risk (open K-G III). Outcomes were compared between periods before (“PRE”; 1/1/2017-9/30/2019) and after (“POST”; 10/1/2019-6/30/2020) implementation. Results: Among 487 open hepatectomies (PRE: 374, POST: 113), 55.0% (n=268) were Low-Intermediate and 45.0% (n=219) were High-Risk. Major complications were similar PRE/POST: Low-Intermediate (PRE: 7.8%, POST: 9.4%, p =0.681) and High (PRE: 18.9%, POST 10.0%, p =0.139). RSPHP implementation reduced median LOS for both Low-Intermediate (4 to 3.5 days, p =0.009) and High (5 to 4 days, p =0.022) patients. RSPHPs decreased LOS variation, reflected in mean and standard deviation (SD) for all patients (PRE 5.5 ± 7.5 vs. POST 4.4 ± 2.8 days). There was no difference in 90-day readmission rates between PRE (12.6%) and POST (8.8%) periods, p =0.278. Conclusions: The creation and implementation of RSPHPs reduced LOS without increasing readmissions after hepatectomy. These generalizable RSPHPs preoperatively stratify patients a priori into pathways for individualized preoperative discussions on realistic postoperative complications and LOS expectations. Funding Information: The authors have nothing to disclose with regard to direct and indirect financial support by extramural sources for this study or related studies. Declaration of Interests: The authors have nothing to disclose for conflicts of interest. Ethics Approval Statement: The Institutional Review Board at the University of Texas MD Anderson Cancer Center approved this study (PA19-0424).